Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanism of Action of Ketamine's Antidepressant Effects in Treatment-Resistant Major Depression
NCT03973268Phase 1Recruiting
- Sponsor
- National Institute of Mental Health
- Start
- Jan 2020
- Primary completion
- Feb 2027
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of perampanel in major depressive disorder (MDD) (3 arms), sponsored by National Institute of Mental Health. Primary endpoint: Montgomery-Asberg Depression Rating Scale at Day 7. Started Jan 2020; status: recruiting.
02
Drugs
perampanel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03973268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03973268.